{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:10:58Z","timestamp":1788379858719,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01220","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T11:42:32Z","timestamp":1540899752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing"],"prefix":"10.3389","volume":"9","author":[{"given":"Souad","family":"Moudallel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Steurbaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B3","first-page":"376","article-title":"Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting","volume":"7","author":"Armbruster","year":"2014","journal-title":"Am. Health Drug Benefits"},{"key":"B4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMp1714987","article-title":"The psychology of clinical decision making - implications for medication use","volume":"378","author":"Avorn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.amjmed.2016.05.041","article-title":"Evaluation of dose-reduced direct oral anticoagulant therapy","volume":"129","author":"Barra","year":"2016","journal-title":"Am. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/1076029615614395","article-title":"PRescriptiOn PattERns of oral anticoagulants in nonvalvular atrial fibrillation (PROPER study)","volume":"23","author":"Basaran","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B7","unstructured":"Bayer\n          Xarelto Summary of the Product Characteristics2016"},{"key":"B8","unstructured":"Boehringer-Ingelheim\n          Pradaxa Summary of the Product Characteristics2016"},{"key":"B9","unstructured":"Eliquis Summary of the Product Characteristics2016"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur. Heart J."},{"key":"B11","unstructured":"Lixiana Summary of the Product Characteristics2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ijcard.2017.07.012","article-title":"Atrial fibrillation and use of antithrombotic medications in older people: a population-based study","volume":"249","author":"Ding","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated european heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1586\/14779072.2013.824181","article-title":"A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE","volume":"11","author":"Hess","year":"2013","journal-title":"Exp. Rev. Cardiovasc. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11239-016-1435-3","article-title":"Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants","volume":"43","author":"Howard","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4212\/cjhp.v69i5.1596","article-title":"Prescribing of direct oral anticoagulants in atrial fibrillation based on estimation of renal function using standard and modified cockcroft-gault equations: a retrospective analysis","volume":"69","author":"Kucey","year":"2016","journal-title":"Can. J. Hosp. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMc1100734","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"364","author":"Landman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1177\/1060028014540868","article-title":"Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study","volume":"48","author":"Larock","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations","volume":"10","author":"Lutz","year":"2017","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"603.e601","DOI":"10.1016\/j.amjmed.2011.09.030","article-title":"Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation","volume":"125","author":"Mason","year":"2012","journal-title":"Am. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/imj.13118","article-title":"New oral anticoagulants: appropriateness of prescribing in real-world setting","volume":"46","author":"Pattullo","year":"2016","journal-title":"Intern. Med. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/europace\/eux316","article-title":"Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry","volume":"20","author":"Ruiz Ortiz","year":"2018","journal-title":"Europace"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/MAJ.0000000000000349","article-title":"Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation","volume":"348","author":"Sen","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1060028017728295","article-title":"Effect of renal function on dosing of non-vitamin k antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation","volume":"52","author":"Shrestha","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11239-015-1213-7","article-title":"Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients","volume":"40","author":"Smythe","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 european heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B35","volume-title":"Anticoagulants in Non-valvular Atrial Fibrillation","author":"Van Brabandt","year":"2017"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajem.2016.09.047","article-title":"Safety of direct oral anticoagulants: insights from postmarketing studies","volume":"34","author":"Villines","year":"2016","journal-title":"Am. J. Emerg. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1742-1241.2009.02286.x","article-title":"Drug and dietary interactions of the new and emerging oral anticoagulants","volume":"64","author":"Walenga","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/IJGM.S129235","article-title":"Utilization and prescribing patterns of direct oral anticoagulants","volume":"10","author":"Whitworth","year":"2017","journal-title":"Int. J. Gen. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin k antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2015","journal-title":"Clin. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T11:42:41Z","timestamp":1540899761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":40,"alternative-id":["10.3389\/fphar.2018.01220"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01220","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"article-number":"1220"}}